StockData

Lexicon Pharmaceuticals vs NewAmsterdam Pharma

LXRX and NAMS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LXRX and NAMS compare

Lexicon Pharmaceuticals grew revenue faster over the last twelve months (−29.0% versus −88.9% for NewAmsterdam Pharma).

Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −147% compared with −3644% at NewAmsterdam Pharma.

NewAmsterdam Pharma scores higher on the StockData Score (6 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLXRXNAMS
Size and price
Market cap$792M–
Share price$1.78$19.39
Change, 1 year19.5%−49.4%
Change, 5 years−62.4%98.1%
Beta (5Y)0.011.57
Employees81100
StockData Score
Total score56 (better)
Valuation score00
Growth score1 (better)0
Performance score2 (better)1
Health score25 (better)
Dividend score00
Valuation
P/S19.1×–
P/B4.5×–
Fair value$0.950–
Margin of safety−87.4%–
Growth
Revenue growth (TTM)−29.0% (better)−88.9%
Revenue growth, 5Y average15.7%–
Profitability
Gross margin99.1%–
Operating margin−131% (better)−3432%
Net margin−147% (better)−3644%
FCF margin–−2018%
Return on equity−40.2%−36.8% (better)
Return on invested capital−163% (better)−1046%
Financial health
Debt / equity0.29 (better)0.00
Current ratio13.37 (better)9.03
Altman Z-score−4.87–
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions81.9%–
Held by insiders–22.0%
Insider net buying, 12 months$2.8M (better)−$63.0M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.